Terapia Medica Del Carcinoma Prostatico

Huggins C. , Hodges C.V. : Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1; 293 (1941).

Brendler H. : Adrenalectomy and ipofisectomy for prostatic cancer. Urology, 2; 99 (1973).

Walsh P.C. , Siiteri P.K. : Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J. Urol., 114; 254 (1975).

Johnson D.E. , Kaesler K.E. , Ayala A.G. : Megestrol acetate for treatment of advanced carcinoma of the prostate. J. Surg. Oncol., 7; 9 (1975).

Geller J. , Albert J. , Yen S.S.C. : Treatment of advanced cancer of prostate with megestrol acetate. Urology, 12; 537 (1978).

Jacobo E. , Schmidt J.D. , Weinstein S.H. , Flocks R.H. : Comparison of flutamide (SCH-13521) and diethyl-stibestrol in untreated advanced prostatic cancer. Urology, 8; 231 (1976).

Prout G.R. jr. , Irwin R.J. jr. , Kliman B. , Daly J.J. , McLaughlin R.A. , Griffin P.P. : Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis. J. Urol., 113; 834 (1975).

Sogani P.C. , Whitmore W.F. jr. : Experience with flutamide in previously untreated patients with advanced prostatic cancer. J. Urol., 122; 640 (1979).

MacFarlane J.R. , Tolley D.A. : Flutamide therapy for advanced prostatic cancer: a phase II study. Brit. J. Urol., 57; 172 (1985).

Bridge R.W. , Scott W.W. : A new antiandrogen, SH-714. Invest. Urol., 2; 99 (1964).

Markewitz M. , Veenema R.J. , Fingerhut B. , Nehme-Haily D. , Sommers S.C. : Cyproterone acetate (SH 714) effect on histology and nucleic acid synthesis in the testes of patients with prostatic carcinoma: a preliminary report. Invest. Urol., 6; 638 (1969).

Geller J. , Vazakas G. , Fruchtman B. , Newman H. , Nakao K. , Loh A. : The effect of cyproterone acetate in advanced carcinoma of the prostate. Surg., Gynec. & Obst., 127; 748 (1968).

Walsh P.C. , Korenman S.G. : Mechanism of androgenic action: effect of specific intracellular inhibitors. J. Urol., 105; 850 (1971).

Scott W.W. , Schirmer H.K.A. : A new oral progestional steroid effective in treating prostatic cancer. Trans. Amer. Ass. Genito-Urin. Surg., 58; 54 (1966).

Wein A.J. , Murphy J.J. : Experience in the treatment of prostatic carcinoma with cyproterone acetate. J. Urol., 109; 68 (1973).

Smith R.B. , Walsh P.C. , Goodwin W.E. : Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J. Urol., 110; 106 (1973).

Jacobi G.H. , Altwein J.E. , Kirth K.H. , Basting R. , Hohenfellner R. : Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomized trial. Brit. J. Urol., 52; 208 (1980).

Trachtenberg J. : The effect of the chronic administration of a potent luteinizing hormone releasing hormone analogue on the rat prostate. J. Urol., 128; 1097 (1982).

Corbin A. : From contraception to cancer: a review of the therapeutic application of LH-RH analogue as antitumor agents. Yale J. Biol. Med., 55; 27 (1982).

Wenderoth U.K. , Jacobi G.H. : Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate: a new approach to the classic concept. World J. Urol., 1; 40 (1983).

Waxman J.H. , Wass J.A. , Hendry W.F. , Whitfield H.N. , Bary P. , Besser G.M. , Malpos J.S. , Oliver R.T. : Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotropin releasing hormone. Brit. J. Urol., 55; 737 (1983).

Soloway M.S. : Newer methods of hormonal therapy for prostate cancer. Urology, 24; Suppl. 5, 30 (1984).

Williams G. , Allen J.M. , O'Shea J.P. , Mashiter K. , Doble A. , Bloom S.R. : Prostatic cancer: treatment with long-acting LH-RH analogue. Brit. J. Urol., 55; 743 (1983).

Van Cangh P.J. , Opsomer R. : Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI 118.630). J. Urol., 137; 61–64 (1987).

Smith J.A. jr. : Luteinizing hormone-releasing hormone (LH-RH) analogues in treatment of prostatic cancer. Urology, 27; Suppl., 9–15 (1986).

Parker M.C. , Cook A. , Riddle P.R. : Is delayed treatment justified in carcinoma of the prostate? Brit. J. Urol., 57; 724–8 (1985).

Klugo R.C. , Farah R.N. , Cerny J.C. : Bilateral orchidectomy: response of serum testosterone and clinical response to subsequent estrogen therapy. Urology, 17; 49–50 (1981).

Smith J.A. jr. : New methods of endocrine management of prostatic cancer. J. Urol., 137; 1–10 (1987).

Murphy G.P. , Priore R.L. , Scardino P.T. : Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. Urology, 32; 33–40 (1988).

Eisenberger M.A. : A re-evaluation of non hormonal citotoxic chemotherapy in the treatment of the prostate carcinoma. J. Clin. Oncol., 3; 827 (1985).

Whitmore W.F. : The natural history of prostate carcinoma. Cancer, 23; 1104 (1973).

Johnson D.E. , Babaian R.J. , Swanson D.A. , Von Eschenbach A.C. , Wishnow K.I. , Tenney D. : Medical castration using megestrol acetate and minidose estrogen. Urology, 31; 371–374 (1988).

Trachtenberg J. : Ketoconazole therapy in advanced prostatic cancer. J. Urol., 132; 61–63 (1984).

Labrie F. , Dupont A. , Belanger A. , Giguere M. , Lacourisère Y. , Emond J. , Monfette G. , Bergeron V. : Combination therapy with flutamide and castration (LH-RH agonist or orchidectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Steroid Biochem., 23; 833–841 (1985).

Veterans Association Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg., Ginec. & Obst., 124; 1011–1017 (…).

Robinson M.R.G. , Chandrysek-ran S. , Newling D.W.W. , Richards B. , Smith P.H. : Low-dose Doxorubicin in the management of advanced carcinoma of the prostate. Brit. J. Urol., 55; 747–748(1983).

Clark P. , Houghton L. : Subcapsular orchidectomy for carcinoma of the prostate. Brit. J. Urol., 49; 419–425, 1977.

Crawford D.E. , McLeod D. , Dorr A. , Spaulding J. , Benson R. , Eisenberg M. , Blumenstein B. : Treatment of newly diagnosed stage D₂ prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036. Amer. Urol. Ass. 1988.

Denis L. , Newling D. , Smith P. , Silvester R. , Mahler C. , De Pauw M. : Orchidectomy versus total androgen blockade: a phase III EORTC 30853 study. Amer. Urol. Ass. 1988.

Khoury S. : Estracyt: update 1986. Progress in prostatic cancer, 97–107, Padova 1986.

Kaisary A.V. (British prostate group): LH-RH agonist “Zoladex” (ICI 118.630) versus surgical orchidectomy in the treatment of metastatic carcinoma of the prostate. Amer. Urol. Ass. 1988.

Eichenberg T. , Trachtenberg J. : Hight dose ketoconazole therapy of patients with metastatic hormone indipendent prostatic cancer. Amer. Urol. Ass. 1988.

Yagoda A. : Chemotherapy of prostatic cancer. International Symposium on advances in urologic oncology. Sanremo 1987.

Walsh P.C. : Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol. Clin. N. Amer., 2; 125 (1975).

Pont A. , Williams P.L. , Loose D.A. , Feldman D. , Reitz R.E. , Bochra C. , Steven D.A. : Ketoconazole blocks adrenal steroid synthesis. Ann. Intern. Med., 97; 370 (1982).

Pont A. , Williams P.L. , Azhar S. , Reitz R.E. , Bochra C. , Smith E.R. , Stevens D.A. : Ketoconazole blocks testosterone synthesis. Arch. Intern. Med., 142; 2137 (1882).

Catalona W.J. , Scott W.W. : Carcinoma of the prostate. J. Urol., 119; 1 (1978).

Crawford E.D. , Foote E.J. : Total androgen suppression: Are there any advantages? The uses of combined therapy in the treatment of advanced prostate adenocarcinoma. Seminars in Urology, 6; 291–302 (1989).